Follow‐Up and Comparative Assessment of SARS‐CoV‐2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA‐1273 Heterologous Booster Vaccination

<h3>Background</h3><p dir="ltr">Priming with ChAdOx1 followed by heterologous boosting is considered in several countries. Nevertheless, analyses comparing the immunogenicity of heterologous booster to homologous primary vaccination regimens and natural infection are lack...

Full description

Saved in:

Bibliographic Details
Main Author:	Salma Younes (6424865) (author)
Other Authors:	Eleonora Nicolai (496034) (author), Massimo Pieri (5023022) (author), Sergio Bernardini (504056) (author), Hanin I. Daas (21841853) (author), Duaa W. Al‐Sadeq (21841856) (author), Nadin Younes (4863280) (author), Farah M. Shurrab (21841859) (author), Parveen B. Nizamuddin (21841862) (author), Fathima Humaira (21841865) (author), Nader Al‐Dewik (14777014) (author), Hadi M. Yassine (21841868) (author), Laith J. Abu‐Raddad (21841871) (author), Ahmed Ismail (2671822) (author), Gheyath K. Nasrallah (21841874) (author)
Published:	2024
Subjects:	Biological sciences Genetics Biomedical and clinical sciences Clinical sciences Immunology Health sciences Epidemiology Public health antibodies anti- S1-IgA anti- S-RBD IgG booster COVID-19 immune response neutralizing antibody vaccination
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Follow‐Up and Comparative Assessment of SARS‐CoV‐2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA‐1273 Heterologous Booster Vaccination

Similar Items